



For additional information, contact:

Carin Rockind
Team NEO
216.363.5426

crockind@teamneo.org

Vijay Puntambekar
AIM Pharmakon, Inc.
631-506-8430 (Phone/Fax)
631-816-1269 (Mobile)

info@aimpharmakon.com
www.aimpharmakon.com

AIM Pharmakon Selects Cleveland for Research and Manufacturing Center
*Global Pharmaceuticals Firm Follows Trend of Global Biomedical Companies
Expanding to Northeast Ohio*

Cleveland, OH, December 7, 2009 – AIM Pharmakon Incorporated (API), a pharmaceutical and dietary supplement company, announces that the company will create a Research & Development and manufacturing facility in Cleveland to expand product lines for global markets. API is investing \$2 Million in capital to build the lab, where once fully implemented, the company will employ approximately 40 staff with an average annual salary of \$55,000, totaling \$2.2 Million annual payroll. A leader in cardiovascular products, the company chose Cleveland because of the region's strong biomedical base and expertise in cardiovascular care.

With this center, API and its affiliate Global Life Science LLC, USA (GLS USA), is developing "fast-turnaround" pharmaceutical manufacturing projects in emerging markets, starting with North Africa and the sub-Saharan regions in Africa, where substandard and counterfeit products dominate the market, and which are deprived of cutting-edge and proven product choices.

"We chose Cleveland to leverage the scientific base for product development," says Vijay Puntambekar, the president of API. "The Global Cardiovascular Innovation Center (GCIC) first introduced us to Cleveland, and since the Cleveland Clinic is the best source for cardiovascular care, the location makes good business sense. We are discussing the opportunity of doing clinical studies at the Cleveland Clinic and other leading healthcare organization in the area." The Cleveland R&D and manufacturing facility will establish brands with clinical studies in order to develop more US FDA compliant and natural alternative therapies for overall cardiovascular and bone health regime. The company has already received commitments from overseas markets for commercialization opportunities.

Tom Waltermire, Team NEO CEO noted, "Northeast Ohio's rich biomedical community and leading healthcare organizations help our region attract companies like AIM Pharmakon.

This investment, and the biomedical growth in Ohio is directly linked to the investment the State has made in the biomedical industry through the Third Frontier Program.”

In addition to the Technology Business Grant and other incentives from the City of Cleveland, the State of Ohio is providing Job Creation Tax Credits to API. Team NEO, Northeast Ohio’s business attraction agent, assisted the organization and the GCIC in securing the opportunity. Pending selection of final location, API will open a temporary office in the incubator located at 10550 Carnegie, in Cleveland, Ohio, connected to Goldstein, Caldwell & Associates (GCA).

“The City of Cleveland is home to healthcare industry leaders and our Technology Business Grant builds on that strength,” says Mayor Frank G. Jackson. “This program in conjunction with our skilled workforce helps to attract technology companies to our region. These new jobs help us retain our talented young people who graduate from our colleges and universities.”

About AIM Pharmakon Incorporated:

AIM Pharmakon Incorporated (API) is an S-Corporation registered in the State of New York in the year 2005. The company has a branch office in Tokyo, Japan and a wholly owned subsidiary in Mumbai India with functional offices and staff. API is a project management and marketing company and offers an array of niche marketing, branding and sales consulting services for facilitating pharmaceutical and nutraceutical commerce — both foreign and domestic — within two of the largest healthcare markets in the world: the US and Japan.

API is dedicated to improve product design achieving enhanced effective delivery systems and high safety levels. The API portfolio includes therapeutic products for cardiovascular and bone health. Under the GLS labels the pipeline includes products with anti-viral and immunomodulation characteristics. The company is offering a niche portfolio of brands for health maintenance, wellness and longevity through an eclectic product mix. Current approaches in supplement dosage forms are at times encumbered by bioavailability-specific deficiencies and may result in sub-therapeutic delivery of actives. API's preservative-free liquid concentrate formulation designs, in specific combinations, address these challenges effectively.

For operational efficiency, legal, and regulatory reasons, a sister company to API, AIM Pharmakon International Incorporated (APII), was formed in 2008. APII is an S-Corporation registered in the State of New York and is dedicated to R&D and technical projects. APII is registered with US FDA for manufacturing products in a laboratory located in Long Island, New York.

About Team NEO:

Team NEO advances Northeast Ohio’s economy by attracting businesses worldwide to the 16-county Cleveland Plus region. The organization is a joint venture of the region's largest metro chambers of commerce. Since 2007, the organization has attracted 29 new companies, more than 3,100 new jobs and \$95M in annual payroll to Northeast Ohio, leading to a total annual regional payroll benefit of \$260M.

Contact Information:

Carin Rockind, Vice President Marketing and Communications
Team NEO
216.363.5426
crockind@teamneo.org
www.teamneo.org

#